T1	Participants 129 228	patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study
T2	Participants 351 399	patients with non-small-cell lung cancer (NSCLC)
T3	Participants 1291 1384	147 patients were randomized (median age: 60Â±8 years, PS 0/1/2: 44/83/20 patients; males: 78%
